Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANACEA: Acetazolamide for Sleep Apnea
NCT05804084Phase 2Recruiting
- Sponsor
- University of California, San Diego
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetazolamide in obstructive sleep apnea (OSA) (2 arms), sponsored by University of California, San Diego. Primary endpoint: Apnea Hypopnea Index at 4 weeks. Started May 2023; status: recruiting.
02
Drugs
acetazolamide
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05804084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804084.